,

Beyond Science: Future of Biotech & Healthcare: Harnessing Inventive Approaches – Kalkine Media

February 2, 2022

Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Kalkine Media to discuss the company’s innovative pipeline of personalised cancer therapies. The company is developing customised approaches to treating cancer including targeted and cellular therapies.

“With the advent of a pandemic, innovations in the field of medical healthcare and biotechnology have gained momentum. The need of the hour and a strong dependence on the medical system pushed these sectors to a new high. The biggest benefactors of the recent rally are the healthcare technology and wellness solution related players, who have been involved in exploring, developing, and operating such beneficial projects,” – Kalkine Media.

Watch the full interview below.

Related Post

This investor centre was built by Reach Markets

©2022 Reach Markets

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
×

Any advice is general only

Any advice provided by Reach Markets, the Lead Manager on this offer, including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice.

×

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.